These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 8439674)

  • 1. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

  • 2. Finding a rational approach to ESA therapy--for payers and patients.
    Messana A
    Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
    [No Abstract]   [Full Text] [Related]  

  • 3. Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients.
    Powe NR; Griffiths RI; Anderson GF; de Lissovoy G; Watson AJ; Greer JW; Herbert RJ; Whelton PK
    Am J Kidney Dis; 1993 Oct; 22(4):557-67. PubMed ID: 8213796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant erythropoietin. The effect of the marketplace on socialized patient care.
    Besarab A; Erslev AJ
    ASAIO J; 1993; 39(2):85-6. PubMed ID: 8324265
    [No Abstract]   [Full Text] [Related]  

  • 5. Erythropoietin claims monitoring policy: implications of the October 2006 update continuing.
    Messana T
    Nephrol Nurs J; 2006; 33(6):660-3; quiz 664-5. PubMed ID: 17219727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rebates for anti-anemia drugs draw response from FDA, CMS.
    Sipkoff M
    Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
    [No Abstract]   [Full Text] [Related]  

  • 7. Erythropoietin claims monitoring policy: implications for clinical practice.
    Messana T
    Nephrol Nurs J; 2006; 33(2):209-13, 222; quiz 214-5. PubMed ID: 16613415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states.
    Thamer M; Richard C; Ray NF; Greer JW; Cotter DJ; Pearson BC
    Am J Kidney Dis; 1996 Aug; 28(2):235-49. PubMed ID: 8768919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin & ESRD payments: a promising policy outcome?
    Roe W
    Nephrol News Issues; 1989 Sep; 3(9):34-5. PubMed ID: 2682270
    [No Abstract]   [Full Text] [Related]  

  • 10. Trends in use, cost, and outcomes of human recombinant erythropoietin, 1989-98.
    Greer JW; Milam RA; Eggers PW
    Health Care Financ Rev; 1999; 20(3):55-62. PubMed ID: 10558020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicare and erythropoietin.
    Steinbrook R
    N Engl J Med; 2007 Jan; 356(1):4-6. PubMed ID: 17202449
    [No Abstract]   [Full Text] [Related]  

  • 12. How dialysis is paid for: what the dialysis medical director should know, and why.
    Deoreo PB
    Semin Dial; 2008; 21(1):58-62. PubMed ID: 18086259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report from the University Healthsystem Consortium.
    Int J Technol Assess Health Care; 1999; 15(2):437-8. PubMed ID: 10507201
    [No Abstract]   [Full Text] [Related]  

  • 14. HCFA: failing to acknowledge the unique characteristics of the ESRD patient.
    Kanter A; Nidetz M
    Nephrol News Issues; 1990 Feb; 4(2):23-6, 31. PubMed ID: 2320135
    [No Abstract]   [Full Text] [Related]  

  • 15. Medicare program; coverage of epoetin (EPO) used by competent home dialysis patients--HCFA. Final rule.
    Fed Regist; 1994 Jan; 59(6):1278-85. PubMed ID: 10133081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost of treating predialysis patients with recombinant human erythropoietin.
    Durand-Zaleski I; Goldfarb B; Blum-Boisgard C; Drüeke T; Kreis H
    Nephrol Dial Transplant; 1993; 8(4):311-4. PubMed ID: 8390004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The possible effects of CMS's 'non-decision' on a national coverage decision for ESA therapy.
    Cotter D; Thamer M; Zhang Y
    Nephrol News Issues; 2011 Aug; 25(9):15-6, 18. PubMed ID: 21905526
    [No Abstract]   [Full Text] [Related]  

  • 18. Medicare payment options for recombinant erythropoietin therapy.
    Sisk JE; Gianfrancesco FD; Coster JM
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):93-7. PubMed ID: 1928087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin for anemia.
    Med Lett Drugs Ther; 1989 Sep; 31(801):85-6. PubMed ID: 2671624
    [No Abstract]   [Full Text] [Related]  

  • 20. Selected research topics.
    Am J Kidney Dis; 1991 Nov; 18(5 Suppl 2):96-104. PubMed ID: 1951363
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.